Guardant Health Inc. (GH)
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health: Leveraging Liquid Biopsy Testing Momentum
Guardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing. GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth. Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH's revenue momentum and market outperformance.
Guardant Health, Inc. $GH Shares Bought by Aquatic Capital Management LLC
Aquatic Capital Management LLC increased its position in Guardant Health, Inc. (NASDAQ: GH) by 17.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,576 shares of the company's stock after acquiring an additional 27,612 shares during the period.
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Compared to Estimates, Guardant Health (GH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.62 per share a year ago.
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health: Look For Explosive Revenue Growth Ahead
Guardant Health, Inc. is rated a Buy, driven by explosive growth potential in cancer and multi-disease screening, notably via its Shield blood test. GH's Shield is the first FDA-approved blood test for primary colorectal cancer screening, with rapid early adoption and significant pricing power due to ADLT status. GH's integrated platform, product breadth, and first-mover advantage in blood-based CRC screening position it to take share from Natera and expand into new markets.
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth
Guardant Health is rated a strong buy, driven by its Shield blood-based colorectal cancer screening and a transformative collaboration with Quest Diagnostics. GH's Shield test addresses major barriers to screening, expanding access to 50 million Americans and driving a 335% YoY increase in screening volumes. Revenue growth remains robust, with FY2025 revenue at $981 million (+33% YoY) and Q4 preliminary revenue of $280 million (+39% YoY), outpacing peers.
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
Here is how Guardant Health (GH) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts
Guardant Health, Inc.'s Shield ADLT reimbursement, Quest, and guidance raise show good adoption momentum. These positives keep me bullish on GH stock. Their oncology business remains the revenue anchor. Biopharma & Data also came in with good margins and provided some diversification. GH's recent Q3 report showed growing revenues, more Shield tests, and, ex-Screening, they became cash flow positive earlier than expected.
